Inducible overexpression of c-Jun in MCF7 cells causes resistance to vinblastine via inhibition of drug-induced apoptosis and senescence at a step subsequent to mitotic arrest
Introduction
Microtubule inhibitors, especially vinca alkaloids and paclitaxel and its derivatives, are widely used in cancer chemotherapy. The primary mechanism of action of these drugs is to bind to tubulin or microtubules and disrupt mitotic spindle dynamics leading to M-phase arrest [1]. In general, mitotic arrest leads to cell death by apoptosis. However, if apoptosis is suppressed or mitotic checkpoint signaling perturbed, other outcomes, such as aneuploidy, mitotic catastrophe, or senescence, can result [2], [3], [4], [5]. There is a great deal of interest in unraveling the molecular links between mitotic arrest and the eventual outcome, whether it is the immediate or eventual death of the cell, or the survival of an impaired cell. Information in this area is critical as it contributes to our knowledge of basic cellular processes and is essential for a better understanding of the mechanism of action of drugs that interfere with microtubule dynamics.
Our previous studies in KB-3 cells have shown that vinblastine activates the c-Jun NH2-terminal protein kinase (JNK) signal transduction pathway, leading to phosphorylation and activation of c-Jun, and in turn activation of AP-1-dependent transcription [6], [7], [8]. Through an auto-amplification loop involving AP-1 sites in the c-Jun promoter, these events result in a robust increase in c-Jun protein expression. Indeed, we have observed that vinblastine causes highly increased c-Jun expression in all cell lines examined to date, suggesting it is a common and perhaps universal response to microtubule inhibition.1 While it is established that c-Jun plays diverse roles in numerous cellular functions, including cell proliferation, differentiation, and death, its precise role in cellular responses to microtubule inhibitors is controversial. Theoretically, increased c-Jun expression could represent a protective mechanism in aid of cell survival; a destructive mechanism actively involved in the cell death process; or may simply be a bystander event with no direct role in the response to mitotic block.
Stable expression of a c-Jun dominant-negative, TAM-67, in KB-3 cells caused a modest resistance to vinblastine and a delay in caspase activation induced by the drug [6]. However, these properties were context-dependent, in that the TAM-67-expressing cells were resistant only when cells were exposed to drug for short intervals, and relative to control cells were not resistant upon continuous drug treatment.2 More recent studies indicated that the kinetics and extent of apoptosis are similar for both wild-type and c-Jun knockout fibroblasts [9]. In contrast, fibroblasts expressing high levels of human c-Jun were found to be highly resistant to vinblastine [9]. However, cell systems stably expressing dominant-negative forms of a multi-functional transcription factor or with specific genetic lesions do not necessarily represent the best models because of possible cellular adaptation and compensatory mechanisms.
In order to avoid these potential drawbacks we sought to determine the effect of c-Jun inhibition or c-Jun overexpression on vinblastine sensitivity in a more controlled and defined system. For this purpose we utilized MCF7 cells that have been developed to express either the c-Jun dominant-negative TAM-67 or human c-Jun under the control of an inducible promoter [10]. Using the Tet-off system, TAM-67 or c-Jun can be expressed in a manner that is dependent upon the removal of doxycycline from the medium. In this study, we exploited this powerful system to investigate the role of c-Jun and its inhibition on the sensitivity of breast cancer cells to vinblastine. We show that MCF7 cells are highly similar to KB-3 cells in that they exhibit a robust increase in c-Jun expression, c-Jun phosphorylation, and AP-1 activation in response to vinblastine treatment. While inducible TAM-67 expression blocks these events as predicted, there is no change in the sensitivity of the cells to vinblastine. In contrast, inducible overexpression of c-Jun renders the cells markedly resistant to vinblastine, through a mechanism that operates post-mitotic block to prevent drug-induced apoptosis and senescence.
Section snippets
Materials
Flag-tag antibody was obtained from Sigma Chemical (St. Louis, MO). C-terminal c-Jun antibody (sc-44) and actin antibody (sc-1616) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA) and N-terminal c-Jun antibody (J319200) was from Transduction Laboratories (San Diego, CA). Phospho-c-Jun (Ser63) antibody (9261S) was from Cell Signaling (Beverly, MA). For immunoblotting primary antibodies were used at 1:1000 dilution and secondary antibodies at 1:5000 dilution.
Cell lines
MCF7 cells were purchased
Vinblastine induces c-Jun expression and phosphorylation in MCF7 cells
MCF7 cells were treated with vinblastine and extracts prepared and analyzed for c-Jun expression and JNK-mediated phosphorylation by immunoblotting (Fig. 1). c-Jun expression was barely detectable in control cells but strongly induced after vinblastine treatment, with expression sustained over a prolonged period of 6–30 h. c-Jun amino-terminal phosphorylation, evaluated with a phospho-specific (Ser63) c-Jun antibody, followed a similar time-course. These results are very similar to our previous
Discussion
c-Jun was originally identified as one of the immediate-early mitogen regulated genes [14]. A role in cell cycle regulation has been clearly established. One mechanism appears to be due to the ability of c-Jun to transcriptionally down-regulate p53 and in turn the p53-regulated gene p21, thus removing a block on cell cycle progression [15]. Another mechanism involves the induction of cyclin D1 by AP-1 [16]. c-Jun and its upstream regulator JNK have also been implicated in apoptosis [17]. c-Jun
Acknowledgements
This work was supported by National Institutes of Health Grant CA-75577 (to TCC). We thank Christopher Lyle for assistance with the figures.
References (25)
- et al.
AP-1 activation and altered AP-1 composition in association with increased phosphorylation and expression of specific Jun and Fos family proteins induced by vinblastine in KB-3 cells
Biochem Pharmacol
(2001) - et al.
The JNK, ERK and p53 pathways play distinct roles in apoptosis mediated by the antitumor agents vinblastine, doxorubicin, and etoposide
Biochem Pharmacol
(2003) - et al.
Role of c-Jun in cellular sensitivity to the microtubule inhibitor vinblastine
Biochem Biophys Res Commun
(2005) - et al.
Vinblastine-induced apoptosis is mediated by discrete alterations in subcellular location, oligomeric structure, and activation status of specific Bcl-2 family members
J Biol Chem
(2006) - et al.
c-Jun can recruit JNK to phosphorylate dimerization partners via specific docking interactions
Cell
(1996) - et al.
The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation
Biochim Biophys Acta
(1991) Signal transduction by the JNK group of MAP kinases
Cell
(2000)- et al.
Induction of apoptosis by the anti-tubulin drug colcemid: relationship of mitotic checkpoint control to the induction of apoptosis in HeLa S3 cells
Exp Cell Res
(1994) - et al.
Coupling cell division and cell death to microtubule dynamics
Curr Opin Cell Biol
(1997) - et al.
p53-independent apoptosis and p53-dependent block of DNA rereplication following mitotic spindle inhibition in human cells
Exp Cell Res
(1999)
Microtubules as a target for anticancer drugs
Nat Rev Cancer
Classification of cell death: recommendations of the Nomenclature Committee on Cell Death
Cell Death Differ
Cited by (19)
HZ08, a great regulator to reverse multidrug: Resistance via cycle arrest and apoptosis sensitization in MCF-7/ADM
2010, European Journal of PharmacologyCitation Excerpt :Since more and more evidences have proven the pivotal role of mitochondria in the execution of apoptosis, a synergistic action on intrinsic pathway might therefore be a good strategy to enhance anticancer drug induced death (Ong et al., 2008). Disabled apoptosis, which always associated with tumorigenesis, usually accompanies the inactivation of cell cycle checkpoint and the disturbance of apoptosis related proteins (Duan et al., 2007; Makin and Dive, 2003). These apoptosis regulation factors are determiners of the tumor malignancy level and therapeutic reaction.
Reduction of doxorubicin and oracin and induction of carbonyl reductase in human breast carcinoma MCF-7 cells
2008, Chemico-Biological InteractionsCitation Excerpt :These data were in accordance with a minor increase in reductase activities observed after exposure to DOX or ORC (Figs. 3–5). The human breast carcinoma MCF-7 cell line is frequently used for studies of mode of cytostatics action and mechanisms of drug resistance [27,28]. In the present study, this carcinoma model was used to evaluate biotransformation of DOX and ORC, and to investigate effects of DOX and ORC on carbonyl reducing enzymes.
Bovine dialyzable leukocyte extract modulates AP-1 DNA-binding activity and nuclear transcription factor expression in MCF-7 breast cancer cells
2008, CytotherapyCitation Excerpt :In contrast with our results, other studies have reported that vinblastine-induced cell death is associated with c-Jun protein expression, c-Jun phosphorylation and AP-1 activation in MCF-7 cells. Although c-Jun expression inhibited cell death, it did not affect the ability of vinblastine to induce mitotic arrest, indicating that c-Jun expression plays a protective role in the cellular response to vinblastine and operates a post-mitotic block to inhibit drug-induced apoptosis [17]. This suggests that bDLE can induce apoptosis in MCF-7 breast cancer cells [8] without forming bDLE-resistant MCF-7 cells, but this theory must be studied.
Short-term transcriptomic response to plasma membrane injury
2021, Scientific Reports